Fremman Capital Acquires Stingray Healthcare: Enhancing Cancer Treatment
Stingray Healthcare acquired by Fremman Capital
Get the full Stingray Healthcare company profile
Access contacts, investors, buying signals & more

Stingray Healthcare
Undisclosed Amount
November 7, 2025

Fremman Capital
Fremman Capital has acquired Stingray Healthcare for an undisclosed amount, marking a significant corporate transaction in the European healthcare sector.
Stingray Healthcare, formerly known as MedEuropa Group, was established in 2017 with a mission to advance cancer care across Europe.
The acquisition sees Fremman Capital take ownership of a growing network dedicated to supporting the long-term success of cancer treatment centres.
Stingray operates through a unique partnership model, teaming up with medical professionals, healthcare managers, and entrepreneurs.
The company provides capital and strategic expertise to cancer care practices, ensuring they can deliver state-of-the-art treatment and develop their services.
Headquartered in Lausanne, Switzerland, Stingray focuses on radiotherapy and radiosurgery facilities, with a current presence in Germany and France.
Its approach is designed to secure the future of practices, facilitate their development through access to management resources and investments in equipment, and optimise value for practice owners.
This acquisition is strategically significant for Fremman Capital, expanding its portfolio within the critical and specialized European healthcare market, particularly in cancer care.
For Stingray, becoming part of Fremman Capital provides a robust partner to further its mission and accelerate its growth trajectory.
The transaction aims to leverage Fremman's financial and strategic backing to enhance Stingray's existing network, allowing for continued investment in advanced medical technologies and potential geographical expansion.
The synergy between Fremman's investment capabilities and Stingray's operational model is expected to reinforce the alliance's ability to support medical professionals and provide optimal patient care.
The combined entity is poised to strengthen its position as a leading partner for cancer treatment centres, ensuring continued development and high-quality service delivery across its network.
Buying Signals & Intent
Our AI suggests Stingray Healthcare may be interested in:
Unlock GTM Signals
Discover Stingray Healthcare's tech stack and active buying intent signals.
View GTM SignalsTrusted by 200+ sales professionals
Unlock Key Decision-Makers
Get direct access to the key decision-makers at Stingray Healthcare.
Unlock Decision-MakersTrusted by 200+ sales professionals